Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 16/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4565204 | 1.00 | PIK3CB (0.48) | PIK3CBPRMT5WDR77AURKA | |
| SCHEMBL4565470 | 0.99 | PIK3CB (0.48) | PIK3CBPRMT5WDR77AURKA | |
| SCHEMBL4565471 | 0.99 | PIK3CB (0.48) | PIK3CBPRMT5WDR77AURKA | |
| SCHEMBL4565319 | 0.98 | PIK3CB (0.48) | PIK3CBPRMT5WDR77AURKA | |
| SCHEMBL4565313 | 0.98 | PIK3CB (0.48) | PIK3CBPRMT5WDR77AURKA | |
| SCHEMBL4564651 | 0.94 | PIK3CB (0.49) | PIK3CBPRMT5WDR77 | |
| SCHEMBL4564652 | 0.94 | PIK3CB (0.49) | PIK3CBPRMT5WDR77 | |
| SCHEMBL4564467 | 0.94 | PIK3CB (0.49) | PIK3CBPRMT5WDR77AURKA | |
| SCHEMBL1656696 | 0.94 | PIK3CB (0.49) | PIK3CBPRMT5WDR77 | |
| SCHEMBL16798255 | 0.90 | PIK3CB (0.46) | PIK3CBPRMT5WDR77AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016087488-A1 | ADMINISTRATION REGIME FOR AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | WO | claimed |
| EP-3077003-A1 | COMBINATION OF PI3K-INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-12 | — | — | EP | disclosed |
| WO-2016087490-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | WO | disclosed |
| WO-2015082378-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-11 | — | — | WO | disclosed |
| EP-2638045-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Intellectual Property GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062748-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-18 | — | — | WO | disclosed |